What is the 13F Pro Quality Score for BSX?

13F Pro ranks BOSTON SCIENTIFIC CORP (BSX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BSX's current score at https://13fpro.ai/research/BSX (free sign-up required for the full ranking).

Which hedge funds own the most BSX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BSX include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BSX as soon as new 13F filings post.

Where does 13F Pro source BSX data?

All BOSTON SCIENTIFIC CORP fundamentals and ownership data come directly from SEC EDGAR. BOSTON SCIENTIFIC CORP files with the SEC under CIK 885725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BSX in?

BOSTON SCIENTIFIC CORP (BSX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BSX research updated on 13F Pro?

BSX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BOSTON SCIENTIFIC CORP(BSX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 885725 BSX stock profile & AI dashboard →

13F Pro Quality Score

79.9/100

Rank #49 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

79.3/100

Profitability

85.9/100

Balance Sheet

82.3/100

Earnings Quality

84.7/100

Free Cash Flow

71.5/100

Institutional Flow

66.4/100

Revenue Scale

92.8/100

Dilution Risk

47.2/100

BSX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BOSTON SCIENTIFIC CORP (BSX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BSX at 79.9/100 on a 32-signal composite quality model, placing it at rank #49 of 2,879 stocks — the top 5% of the AI-ranked universe. BSX scores in the top quartile across revenue scale (92.8), profitability (85.9), earnings quality (84.7). Shareholder dilution risk is elevated at 47.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BOSTON SCIENTIFIC CORP reports quarterly revenue of $5.2B, net income of $1.3B, an operating margin of 21.2%. Top institutional holders of BSX by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. BSX trades on the NYSE exchange and files with the SEC under CIK 885725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BOSTON SCIENTIFIC CORP directly from SEC EDGAR. BOSTON SCIENTIFIC CORP's 13F Pro composite quality score has ranged between 8 and 80 since 2021, currently 79.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BOSTON SCIENTIFIC CORP

Quirks, history, and lore behind BSX — the kind of stuff that makes a stock memorable.

1
The Basics
A U.S. healthcare company · large-cap · listed on the NYSE · headquartered in Massachusetts.
2
The Numbers
Annual revenue of roughly $14 billion, with products sold in more than 130 countries — keeping hearts, lungs, and other organs in line, literally.
3
The History
Founded in 1979 by two entrepreneurs who saw a gap in the market for less invasive medical devices, growing from a small startup into a global giant through dozens of acquisitions.
4
The Secret
Its bread and butter is minimally invasive procedures — tiny devices threaded through your body so surgeons don't have to crack you open like a walnut.
5
The Lore
Its stent technology helped spark a revolution in cardiology in the 1990s, and a high-profile legal battle with Johnson & Johnson over stent patents became one of the most-watched feuds in medical device history.
6
The Giveaway
If you or someone you love has had a cardiac stent, a pacemaker, or a procedure to zap an irregular heartbeat, there's a good chance the little gadget doing the work has a BSX pedigree.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$5.2B

Net Income

Q1 2026

$1.3B

Free Cash Flow

Q1 2026

$171.0M

Operating Margin

Q1 2026

21.2%

D/E Ratio

Q1 2026

0.43

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+68.9% YoY

$20.07BFY 2025

FY19 $10.73BFY20 $9.91BFY21 $11.89BFY25 $20.07B

Operating Income

+201.3% YoY

$3.61BFY 2025

FY19 $1.52BFY20 $-80.0MFY21 $1.20BFY25 $3.61B

EPS (Diluted)

+181.2% YoY

$1.94FY 2025

FY19 $3.33FY20 $-0.08FY21 $0.69FY25 $1.94

Total Assets

+35.5% YoY

$43.67BFY 2025

FY19 $30.57BFY20 $30.78BFY21 $32.23BFY25 $43.67B

Total Debt

+26.2% YoY

$11.44BFY 2025

FY19 $10.01BFY20 $9.14BFY21 $9.06BFY25 $11.44B

Op. Cash Flow

+142.5% YoY

$4.53BFY 2025

FY19 $1.84BFY20 $1.51BFY21 $1.87BFY25 $4.53B

Metric	FY 2025	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$20.07B +68.9%	$11.89B +19.9%	$9.91B -7.7%	$10.73B +9.3%	$9.82B +8.6%	$9.05B
Operating Income	$3.61B +201.3%	$1.20B +1598.8%	$-80.0M -105.3%	$1.52B +0.8%	$1.51B +17.2%	$1.28B
EPS (Diluted)	$1.94 +181.2%	$0.69 +962.5%	$-0.08 -102.4%	$3.33 +179.8%	$1.19 +1387.5%	$0.08
Total Assets	$43.67B +35.5%	$32.23B +4.7%	$30.78B +0.7%	$30.57B +45.6%	$21.00B +10.3%	$19.04B
Total Debt	$11.44B +26.2%	$9.06B -0.9%	$9.14B -8.6%	$10.01B +41.8%	$7.06B +25.6%	$5.62B
Operating Cash Flow	$4.53B +142.5%	$1.87B +24.0%	$1.51B -17.9%	$1.84B +492.3%	$310.0M -78.3%	$1.43B

Get alerted when BSX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BOSTON SCIENTIFIC CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BSX

BlackRock, Inc.
$8.3B131,822,037 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.0B96,411,568 sh
FMR LLC
$4.7B74,226,395 sh
STATE STREET CORP
$4.3B67,986,847 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.1B33,285,757 sh
PRIMECAP MANAGEMENT CO/CA/
$2.0B32,529,774 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.9B29,796,211 sh
D. E. Shaw & Co., Inc.
$1.5B24,312,352 sh
BANK OF AMERICA CORP /DE/
$1.4B22,756,646 sh
MORGAN STANLEY
$1.4B22,266,664 sh

Fund	Value	Shares
BlackRock, Inc.	$8.3B	131,822,037
VANGUARD CAPITAL MANAGEMENT LLC	$6.0B	96,411,568
FMR LLC	$4.7B	74,226,395
STATE STREET CORP	$4.3B	67,986,847
GEODE CAPITAL MANAGEMENT, LLC	$2.1B	33,285,757
PRIMECAP MANAGEMENT CO/CA/	$2.0B	32,529,774
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.9B	29,796,211
D. E. Shaw & Co., Inc.	$1.5B	24,312,352
BANK OF AMERICA CORP /DE/	$1.4B	22,756,646
MORGAN STANLEY	$1.4B	22,266,664

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BSX on your watchlist

Track score changes the day BOSTON SCIENTIFIC CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BSX a good stock to buy?

13F Pro's AI-powered analysis of BOSTON SCIENTIFIC CORP (BSX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BSX are available on the BSX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BSX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BSX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BOSTON SCIENTIFIC CORP's investment landscape.